Introduction
Acute myeloid leukemia (AML) is characterized by an accumulation of granulocyte or monocyte precursors in the bone marrow. Traditionally, research on the pathogenesis of AML has focused on the analysis of tumor suppressor genes or oncogenes that regulate cell death or proliferation. Disruption of normal differentiation represents another hallmark of AML since leukemic blasts typically display a block in their normal differentiation process at a particular stage (Tenen, 2003) . Although the ultimate relationship between altered proliferation and differentiation in AML remains to be resolved, recent evidence suggests a concept in which disruption of some transcription factors critically affects both cell cycle and differentiation as being important in AML. Whereas the transcriptional control of normal myeloid development has recently been extensively summarized (Friedman, 2002; Rosmarin et al., 2005; Mueller and Pabst, 2006; Rosenbauer and Tenen, 2007) , as well as elsewhere in this issue, this review intends to highlight aspects of transcriptional dysregulation in human AML. The focus is on the transcription factors CCAAT/enhancer binding protein-a (CEBPA), PU.1 and RUNX1.
The main role of CEBPA in hematopoiesis is in the development of granulocytes Friedman, 2002; Tenen, 2003; Rosmarin et al., 2005) . Nonconditional targeted disruption of CEBPA results in a selective block in early granulocyte maturation . Integrity of DNA binding and transactivation, as well as E2F interaction, resulting in downregulation of c-Myc and proliferation arrest is required for CEBPA-dependent granulocytic differentiation (Johansen et al., 2001; Porse et al., 2001 Porse et al., , 2005 . Conditional CEBPA deficiency in adult mice blocks the transition from common myeloid progenitors to granulocyte monocyte progenitors resulting in the accumulation of myeloid blasts in the bone marrow . Mice carrying engineered CEBPA alleles that specifically disrupt the 42 kDa wild-type protein while allowing expression of the dominant-negative 30 kDa isoform regularly develop an AML-like disease (C Nerlov, unpublished data) . Moreover, knock-in mice with a targeted mutation in the CEBPA basic region that specifically inhibits CEBPA-E2F interaction predisposed mice to a myeloproliferative disorder (Porse et al., 2005) . These studies suggest that while disrupting the cell-cycle regulatory function of CEBPA may be sufficient to initiate AML-like transformation of the granulocytic lineage, other CEBPA functions must be preserved in leukemic stem cells.
Sporadic CEBPA mutations in human AML
Eleven groups now have reported the presence of genomic CEBPA mutations in AML patients, with the frequency varying between 5 and 14% (Pabst et al., 2001b; Gombart et al., 2002; Preudhomme et al., 2002; Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Snaddon et al., 2003; Frohling et al., 2004 Frohling et al., , 2005 Bienz et al., 2005; Lin et al., 2005; Smith et al., 2005; Shih et al., 2006) . The mutations can be largely divided into two types (Figure 1) : First, N-terminal frameshift mutations result in premature termination of the fulllength 42 kDa form of the CEBPA protein, while preserving the 30 kDa form initiated further downstream (Pabst et al., 2001b) . The latter inhibits the remaining normal CEBPA 42 kDa protein in a dominant-negative manner. Second, C-terminal in-frame mutations disrupt the basic zipper region, thus affecting DNA binding and homo-and heterodimerization with other CEBP family members (Pabst et al., 2001b All studies so far indicated that AML patients with CEBPA mutations had better relapse-free survival or overall survival. Why CEBPA mutations confer good prognosis remains unclear. There are contradictory studies whether coexisting FLT3-ITD adversely affects the favorable prognosis of CEBPA mutations Bienz et al., 2005) . However, the incidence of FLT3-ITD alterations is not different in CEBPAmutated vs nonmutated patients Bienz et al., 2005 ). There appears to be an association of deletion 9q and CEBPA loss-of-function mutations, suggesting that loss of a critical segment of 9q and disruption of CEBPA function possibly cooperate in the pathogenesis of del(9q) AML (Frohling et al., 2005) . There is a typical immunophenotype of AML blasts with CEBPA mutations with expression of HLA- Bienz et al., 2005; Lin et al., 2005) , with the aberrant expression of the T-cell marker CD7 being particularly noteworthy. Using microarray analysis, AML patients with nonsilent CEBPA mutations express a distinctive gene expression signature (Bullinger et al., 2004; Valk et al., 2004; Keeshan et al., 2006) .
There is a distinct CEBPA mutation pattern in AML patients (Figure 2 ). The majority of the 166 AML patients reported so far with CEBPA mutations have more than one CEBPA mutation (72%) rather than a single mutation (28%). Among the 46 AML patients with a single CEBPA mutation, the predominant types are one frameshift N-terminal mutation (19 patients; 41.3%) or one in-frame C-terminal insertion/deletion mutation (15 patients; 32.6%). The remaining 12 patients (26.1%) had one in-frame N-terminal mutation (one patient), one C-terminal frameshift mutation (four patients) or one in-frame point mutation (seven patients). Among the 120 AML patients with multiple CEBPA mutations, the overwhelming majority (111 patients; 92.5%) had the combination of one N-terminal frameshift mutation and one C-terminal in-frame mutation, with the two mutations typically being located on different alleles. Rarely, one of the two main mutation types is combined with one or several additional point mutations (nine patients; 7.5%). This may have important implications for our understanding why additional genetic abnormalities are hardly ever identified in AML patients with CEBPA mutations, since the most frequent 'second' genomic abnormality in such patients is an additional CEBPA mutation. Since both main types of mutation can occur as sole abnormality at diagnosis, these observations indicate that CEBPA mutations might predispose to the occurrence of an additional CEBPA mutation as a secondary hit, ultimately inducing AML. This would also be consistent with the observation that both CEBPA mutation types do not develop at the time of relapse, indicating that CEBPA mutations are a primary Our analysis above did not include AML patients with the HP196-197ins alteration resulting in a histidine-proline duplication in the second transactivation domain. This histidine-proline duplication has been detected at a frequency between 3.2 and 20% in AML patients, but also between 8.0 and 39% of healthy individuals and thus should be considered a polymorphism (Lin et al., 2005; Wouters et al., 2007) .
Germline CEBPA mutations in human AML
Inherited AML occurs only very rarely outside the setting of a syndrome such as trisomy 21 or defective DNA repair. Three families have recently been reported in whom three, four and two members affected by AML carried germline heterozygous CEBPA mutations (Smith et al., 2004; Sellick et al., 2005; Nanri et al., 2006) . Several aspects are remarkable to these observations. All members affected by AML were of M1 or M2 subtypes, as observed in patients with somatic CEBPA mutations. Leukemic cells typically had Auer rods, aberrant CD7 expression, a normal karyotype, and the marrow showed increased numbers of eosinophils. Germline CEBPA mutations appear to be fully penetrant since all carriers of the mutation developed AML.
The site and type of CEBPA mutations in the three families were almost identical. All members affected by CEBPA mutations had an N-terminal out-of-frame mutation leading to the early truncation of the wildtype protein and preferential production of the 30 kDa dominant-negative isoform. These observations suggest that a substantial decrease in CEBPA function, rather than haploinsufficiency, renders a predisposition to AML in these patients. Intriguingly, five out of the nine affected members in the three families had an additional C-terminal in-frame CEBPA mutation at diagnosis. Again, the C-and the N-terminal mutations have been found on separate alleles. The in-frame C-terminal mutations disappeared upon remission and thus have to be considered somatic mutations (Nanri et al., 2006) . These observations indicate that the germline N-terminal CEBPA mutation predisposed to the occurrence of a somatic C-terminal CEBPA mutation as a secondary hit, ultimately inducing AML after a long latency period. This would be consistent with the observation that N-terminal CEBPA mutations never develop at the time of relapse, suggesting that this type of CEBPA mutation is a primary event in the development of AML.
The prognostic significance of germline CEBPA mutations may differ from the favorable prognosis typically associated with sporadic CEBPA mutations. Whereas the follow-up in one family is only 20 months for affected members, five of the nine familial AML patients with a germline CEBPA mutation have relapsed. Remarkably, relapses occurred after an interval of more than 6 years from first complete remission, which is unusual in AML. This may point to a life-long increased risk to develop overt AML, possibly associated with the germline status of CEBPA deficiency, and this has to be considered if consolidation with allogenous transplantation in first complete remission is discussed with patients with (germ line) CEBPA mutations and intermediate risk cytogenetics-patients who are usually not candidates for such a procedure. Interestingly, no other types of cancer have been reported so far in carriers of germline CEBPA mutations.
The early onset of AML in families with germline CEBPA mutations-all members with AML were between 4 and 39 years at diagnosis-contrasts markedly with the usual age of onset of sporadic AML, reflecting predisposition. This may point to a scenario in which carriers of CEBPA mutations have a population of myeloid cells associated with an increased risk of additional genetic lesions that would lead to AML. Interestingly, the cytogenetic analysis was abnormal in only one member (del6q) affected by germline CEBPA mutations. Despite extensive analysis of other AMLrelated genes, no additional mutations were detected so far in four of the nine carriers of a germline N-terminal CEBPA mutation-with the other five carriers having a somatic C-terminal mutation. This would argue in favor of a relatively straightforward mechanism underlying the accumulation of immature myeloid precursors in the presence of a disabling N-terminal mutation of the CEBPA gene in those patients. Thus, the ultimate causal relationship between germline CEBPA mutation and the development of overt leukemia remains to be clarified.
Transcriptional modulation of CEBPA in acute leukemias
Dysregulated expression is another mechanism to disrupt function of transcription factors crucial for Figure 2 CEBPA mutation pattern in AML patients. Among the 166 AML patients with CEBPA mutations reported so far in 11 different studies, 46 AML patients had a single CEBPA mutation comprising either one frameshift N-terminal mutation ('N sole'; 19 patients; 11.4%), one in-frame C-terminal insertion/deletion mutation ('C sole'; 15 patients; 9%) or various types of mutations ('various sole'; 7.2%; 12 patients who had one in-frame N-terminal mutation (1 patient), one C-terminal frameshift mutation (4 patients) or one point mutation (7 patients)). Among the 120 AML patients with more than one CEBPA mutation, 111 patients (67%) had the combination of an N-terminal frameshift mutation and a C-terminal in-frame insertion/deletion mutation ('N and C'), or one of the two main mutation types is combined with one or several additional point mutations ('N/C w. mut'; 9 patients; 5.4%). AML, acute myeloid leukemia; CEBPA, CCAAT/enhancer binding protein-a normal hematopoiesis. Indeed, CEBPA mRNA expression is suppressed in the presence of the AML1-ETO fusion both in vitro and in vivo. AML-M2 patients with t(8;21) have up to sixfold less CEBPA mRNA than AML-M2 with a normal karyotype (Pabst et al., 2001a) . AML1-ETO is thought to inhibit CEBPA mRNA expression through inhibition of autoregulation (Pabst et al., 2001a) . Interestingly, other leukemic fusion proteins involving CBF family members-such as the AML1-myelodysplastic syndrome (MDS1)-EVI1 or the CBFB-MYH11 fusionhave not been shown to suppress CEBPA mRNA (Helbling et al., 2004 (Helbling et al., , 2005 .
Recently, the lymphoid enhancer-binding factor 1 was shown to be suppressed in the bone marrow of patients with severe congenital neutropenia with a differentiation block of myelopoiesis at the promyelocytic stage (Skokowa et al., 2006) . Interestingly, lymphoid enhancer-binding factor 1 appears to activate the CEBPA promoter at a site between -559 bp and À538 bp. Reconstitution of lymphoid enhancer-binding factor 1 in early hematopoietic progenitors of congenital neutropenia patients restored CEBPA expression and corrected the defective myelopoiesis (Skokowa et al., 2006) . Whether this mechanism is involved in subsets of human AML has not been reported so far.
Apart from AML with AML1-ETO, gene expression array studies have not revealed other subsets of AML patients with consistently suppressed CEBPA mRNA (Bullinger et al., 2004; Valk et al., 2004) -apart from AML patients with erythroleukemias (M6) or megakaryocytic leukemias (M7), in which CEBPA mRNA is decreased. In particular, CEBPA mRNA is equally expressed among granulocytic and monocytic AML subtypes. Given the role of CEBPA for normal neutrophil development, this may be surprising. However, several recent reports have established the importance of CEBPA for monocytic differentiation (Liu et al., 2003; Heath et al., 2004 . The gene expression studies in AML patients contrast with in vitro data indicating that CEBPA mRNA is repressed by FLT3/ITD signaling in 32D cells (Bullinger et al., 2004; Valk et al., 2004; Zheng et al., 2004) . CEBPA repression was overcome in these studies by treatment with an FLT3 inhibitor, CEP-701, in FLT3/ITD-expressing 32D cells (Zheng et al., 2004) .
Finally, a report studying hypermethylation of the CEBPA promoter indicates that 2 out of 23 AML-M2 patients (9%) had methylated CEBPA promoter (Chim et al., 2002) . Possibly, this mechanism warrants further consideration for subsets of AML patients since hypermethylation of the upstream CEBPA promoter region, not the core promoter region as previously reported, is critical in the regulation of CEBPA expression in human lung cancer (Tada et al., 2006) .
Traditionally, CEBP family members are regarded as not being involved in chromosomal translocations in leukemias. Rather, the tumor suppressor function of CEBPA was based on observations of dominantnegative mutations and suppression of CEBPA expression in AML. This view was challenged by two recent reports indicating that five members of the CEBP transcription factor family are targeted by recurrent IGH-translocations in B-cell precursor acute lymphoblastic leukemia (B-ALL) (Chapiro et al., 2006; Akasaka et al., 2007) . Remarkably, such translocations resulted in overexpression of affected CEBPs, including translocations t(14;19)(q32;q13) involving CEBPA. This indicates that not only loss, but also gain of function of CEBPA has leukemogenic potential (Figure 3) . However, many aspects have not been addressed such as why CEBPA deficiency is observed in AML, whereas CEBPA overexpression is seen in B-ALL. Also, at least one CEBPA mutation in AML has been reported whose activation potential in transfection assays exceeded several fold that of the wild-type construct (Pabst et al., 2001b) . In addition, retroviral overexpression of CEBPA in vitro reprograms B cells into macrophages (Xie et al., 2004) , whereas finding CEBPA overexpression in B-ALL with t(14;19)(q32;q13) obviously challenges such a view. However, these reports in human leukemias underline the concept of gene dosage in leukemogenesis indicating that the dosage of CEBPAtoo much or too little-can cause cancer.
Post-transcriptional regulation of CEBPA in myeloid leukemias
Chronic myeloid leukemia in blast crisis is characterized by an arrest of myeloid differentiation, which is not yet evident in chronic phase. Loss of CEBPA function represents an obvious candidate event for this block. Whereas CEBPA mutations are not a frequent event in chronic myeloid leukemia in blast crisis , CEBPA protein-but not its mRNA-is suppressed to undetectable levels in primary cells from patients with chronic myeloid leukemia in blast crisis (Perrotti et al., 2002) . CEBPA protein suppression is mediated at the translational level by interaction of the poly(rC)-binding protein hnRNP E2 with CEBPA mRNA (Perrotti et al., 2002) . Whether hnRNP E2 is involved in post-transcriptional CEBPA suppression in AML remains to be tested. Restoring CEBPA activity in 32D-BCR/ABL cells induced granulocytic differentiation and suppressed leukemogenesis, independently of C E B P A AML " blocked " ALL " induced " , 2006) . Surprisingly, bcr/abl-expressing CEBPA-deficient fetal liver cells failed to induce a myeloid disease in transplanted mice, but caused erythroleukemia instead (Wagner et al., 2006) . Regulating the rate of translation of specific mRNAs is an efficient mechanism of oncogenic proteins to modulate the levels of the corresponding proteins. Such a mechanism was demonstrated for CEBPA in AML with t(3;21) encoding the AML1-MDS1-EVI1 fusion gene (Helbling et al., 2004) . Expression of AML1-MDS1-EVI1 suppressed CEBPA protein in a conditional cell line model and in AML patient samples, whereas CEBPA mRNA remained unchanged (Helbling et al., 2004) . Interestingly, the RNA binding protein calreticulin was strongly activated in AML1-MDS1-EVI1 patients. Calreticulin protein interacts with guanine-cytosine-triplets (GCN) repeats within CEBPA (and CEBPB) mRNAs and thereby efficiently blocks translation of CEBP proteins in vitro and in vivo (Timchenko et al., 2002) . Interestingly, post-transcriptional suppression of CEBPA by activated calreticulin was also observed through the CBFB-MYH11 leukemic fusion protein, indicating that induction of calreticulin binding activity to CEBPA mRNA is a major mechanism involved in the suppression of CEBPA protein in CBF leukemias (Helbling et al., 2005) .
Post-translational inhibition of CEBPA in AML
The list of reports is steadily growing on mechanisms that affect the activity of the CEBPA protein in human AML. Phosphorylation of CEBPA at serine 21 is mediated by extracellular signal-regulated kinases 1 and/or 2, which recognize serine 21 of CEBPA as a substrate through an FXFP docking motif (Ross et al., 2004) . This phosphorylation induces a conformational change in CEBPA such that the transactivation domains of two CEBPA molecules within a dimer move further apart. Activation of FLT3 in human AML appears to block the phosphorylation of CEBPA at serine 21 which may explain the differentiation block of blasts in leukemias with activated FLT3 .
Additional in vitro reports exist on various CEBPA phosphorylation sites (Figure 1) . However, it needs to be addressed in further studies whether they are, indeed, directly involved in particular subsets of myeloid leukemias. Serine 248 is targeted by activated Ras, and PKC inhibitors block the activation of CEBPA by Ras thus impairing the ability of CEBPA to induce granulocytic differentiation (Behre et al., 2002) . In liver tumor cells, the activation of the PI3K/Akt pathway blocks the growth inhibitory activity of CEBPA through PP2A-mediated dephosphorylation of CEBPA on serine 193 leading to a failure of CEBPA to interact with and inhibit cyclin-dependent kinases and E2F (Wang et al., 2004) . Mutation of this site abolished the ability of CEBPA to cause growth arrest (Wang et al., 2004) .
Other post-translational mechanisms of CEBPA modulation remain to be tested in human leukemias, such as whether the composition of heterodimers with other CEBP family members is altered in AML. In particular, heterodimerization with CEBPg and/or CHOP has been shown to modulate CEBP activity in a cell-and isoformspecific manner (Parkin et al., 2002) . Also, the role of repressors of CEBPA activity-such as CA150-has not been addressed in myeloid leukemias (McFie et al., 2006) .
Recently, the Tribbles homolog 2 (Trib2) was shown to inactivate CEBPA and cause AML . Increased expression of Trib2 was detected in a subset of AML patients with a distinct expression profile. This subset comprised one (of two) clusters of patients that were associated with CEBPA mutations (Valk et al., 2004) . While this cluster also contained patients without CEBPA mutations, Trib2 expression was primarily elevated in patients without CEBPA mutations . In vitro assays demonstrated that forced expression of Trib2 changed the 42/30 kDa CEBPA isoform ratio in favor of the oncogenic 30 kDa form. Moreover, activated Trib2 was shown to block the CEBPA 42 kDa wild-type protein by physical interaction, resulting in the proteasomaldependent degradation of CEBPA . This is the second report indicating that deregulation of the translational control of the CEBPA isoform ratio is involved in the pathogenesis of a (very small) group of AMLs-besides the initial report on (much more frequent) N-terminal CEBPA frameshift mutations (Pabst et al., 2001b) . It may point to other subsets of AML patients in which this ratio may also be disturbed. A systematic analysis of leukemic cells of AML patients investigating changes of the CEBPA isoform ratio has not been reported so far, with the main reason being the usually limited quality and quantity of clinical material needed for such an analysis.
Finally, there is evidence that suppressed CEBP activity is involved in the differentiation block of patients with acute promyelocytic leukemia (APL/AML-M3) characterized by the presence of the promyelocytic leukemia retinoic acid receptor alpha (PML/RARA) fusion protein.
Conditional induction of PML-RARA in myeloid U937 cells inhibits expression of CEBPE and decreases CEBPA activity (Truong et al., 2003) . Also, restoring CEBPA activity in leukemic cells from PML-RARA transgenic mice suppresses growth and induces partial differentiation in vitro (Truong et al., 2003) . In vivo, enhanced expression of CEBPA in PML-RARA transgenic mice prolongs survival of such animals (Lee et al., 2006) . All-trans retinoic acid treatment of PML/RARA-positive cell lines (Duprez et al., 2003) and of patients with AML-M3 powerfully induces CEBPB, CEBPE and-to a lesser extent-CEBPA mRNA expression (Mueller et al., 2006a) . All-trans retinoic acid-induced activation of CEBPB then leads to induction of PU.1 through a site in the proximal PU.1 promoter (Mueller et al., 2006a) .
Dysregulation of PU.1 in AML
Given the importance of the transcription factor PU.1 for normal hematopoiesis-as summarized elsewhere in this issue-PU.1 represents another obvious target for disruption in AML. Indeed, mutations of the PU.1 gene were detected in 7% of patients with AML (Mueller et al., 2002) . The mutations decreased the ability of PU.1 to synergize with interacting proteins, such as RUNX1 or JUN, in the activation of target genes such as the macrophage-colony stimulating factor receptor (Mueller et al., 2002) . Interestingly, PU.1 mutations were not detected in leukemic cells from patients with B-ALL (Mueller et al., 2006b) .
PU.1 expression and/or function appears to be suppressed by several leukemogenic fusion products, such as RUNX1-ETO (Vangala et al., 2003) , FLT3-ITD (Mizuki et al., 2003) and PML-RARA (Mueller et al., 2006a) . The suppression of PU.1 expression by PML-RARA in human APL cells is restored by treatment with all-trans retinoic acid, which induces neutrophil differentiation through upregulation of CEBPB which then activates PU.1 expression (Mueller et al., 2006a) . PU.1 expression has been shown to be inversely correlated with levels of PML-RARA in human APL (Mueller et al., 2006a) .
Following these initial reports of suppressed PU.1 function in human AML, the leukemic potential of tumor progenitors with critically reduced PU.1 function has been illustrated by a series of mouse models. Mice with an engineered deletion of the upstream regulatory element (URE) of PU.1 had decreased PU.1 expression and subsequently developed AML (and lymphomas) (Rosenbauer et al., 2004) . Moreover, mice with girradiation-induced myeloid leukemias acquired both a deletion in one copy of chromosome 2, which includes the PU.1 gene locus, and a point mutation in the ETS domain of PU.1, which impaired DNA binding of the other PU.1 allele (Cook et al., 2004; Suraweera et al., 2005) . In addition, deletion of one PU.1 gene copy combined with suppression of the other copy by PML-RARA was reported as the mechanism in mouse APL (Walter et al., 2005) . Whereas these observations indicate that low but detectable amounts of PU.1 might favor the malignant potential of leukemic cells, this view was challenged by a recent report suggesting that complete loss of PU.1 can (also) lead to AML, at least in mice (Metcalf et al., 2006) .
Transcriptional dysregulation in RUNX1 leukemias
The RUNX1/AML1 gene is the most frequent target for chromosomal translocation in AML. Consequently, leukemia research on RUNX1 has traditionally concentrated on investigating RUNX1/ETO, t(8;21); RUNX1/ EVI1, t(3;21); TEL/RUNX1, t(12;21); and CBFb/ MYH11, inv(16). In addition, RUNX1 point mutations were reported in sporadic and familial myeloid leukemia (Osato et al., 1999; Song et al., 1999) . Subsequent studies have confirmed the occurrence of RUNX1 point mutations in AML, predominantly in the M0 subtype (Preudhomme et al., 2000; Langabeer et al., 2002; Matsuno et al., 2003; Roumier et al., 2003; Silva et al., 2003) . Whereas mutations in the C-terminal domain were believed for some time to cluster within the RUNT domain, mutations in the C-terminal region, outside the RUNT domain, have also been identified, predominantly in MDS-AML (Harada et al., 2003) . Finally, RUNX1 mutations turned out to occur at least as frequent as the first mode of RUNX1 alterations, namely, t(8;21), inv(16) and t(12;21), in secondary MDS-AML (Harada et al., 2003) .
Most of the missense point mutations in the RUNX1 gene show loss of DNA binding and transactivation activities (reviewed in Osato, 2004) . Since the majority of the cases are heterozygous, haploinsufficiency appears to be the basis for pathogenesis. However, missense mutations in the three RUNX1 loop-containing regions responsible for DNA binding are defective in DNA binding, but not in heterodimerization, thus exerting a dominant-negative effect of the RUNX1 mutants (Nagata et al., 1999) . Interestingly, studies from pedigrees with familial platelet disorder with predisposition to AML (FPD/AML) suggest that mutations acting via haploinsufficiency have a lower incidence of leukemia than families with mutations acting in a dominant-negative fashion (Song et al., 1999) . This indicates a paradigm that the lower the RUNX1 activity is of a particular mutant, the higher is its leukemogenicity. Moreover, 56.4% of the AML-M0 cases have a biallelic type of mutations, whereas only 2.5% of the RUNX1 mutation patients in other leukemia subtypes show the biallelic type (Osato, 2004) . Therefore, RUNX1 point mutations of the biallelic type are tightly associated with the AML M0 subtype, suggesting that reduction of RUNX1 activity caused by biallelic mutations results in a differentiation block at a very early-undifferentiated-stage, which is characteristic for patients with AML-M0.
Dysregulated transcription factor activity and leukemia therapy
AML is a very heterogeneous cancer at the molecular level. The observation of recurring mutations in genes encoding transcription factors in patients with AML has allowed the identification of new subgroups in AML. Clinical studies have linked the prognostic outcome of patients with AML with such mutations, potentially allowing a more risk-adapted therapeutic approach. For example, the good prognosis of cytogenetically normal AML patients with CEBPA mutations indicates that such patients are no longer candidates for allogenous transplantation in first complete remission.
In the future, to efficiently detect as many transcription factor mutations as possible in AML patients and to modify treatment strategies accordingly, AML patients might be studied at diagnosis by appropriately designed transcription factor microarrays. Such an approach should also consider single-nucleotide polymorphisms in gene promoter sequences because of their quantitative impact on gene expression (Pastinen and Hudson, 2004; Healy et al., 2007) . As is the case for the PU.1 gene, such regulatory regions can be far away from the coding sequences, and it will be a challenge to identify their roles in leukemia.
From a therapeutic view, all-trans retinoic acid treatment of patients with APL remains the sole example of successful introduction of the concept of differentiation therapy in current clinical practice. The difficulties of developing drugs that precisely modulate specific transcription factors and of bringing them to the targeted cells remain the relevant challenges for the development of novel therapeutic concepts targeting at correction of transcription factor activities. However, much hope is put into large drug screens for molecules that specifically modify the endogenous expression or function of transcription factors as well as into therapies involving small interfering RNA molecules targeting specific mRNA.
